Controversial Alzheimer's Drug Faces Critical Test Before F.D.A. Panel
2 min read
If ultimately approved, the drug, aducanumab, made by Biogen, would be the first new Alzheimer's treatment in nearly two decades. Some evidence suggests it slows, but does not stop, cognitive decline.
A federal panel will decide on Friday whether to recommend approval of a controversial but potentially promising Alzheimers drug, which would be the first to come to market in nearly two decades.

The drug, aducanumab, would not stop or reverse dementia, but some evidence suggests it can slow the progression of memory and thinking problems in people with mild or early symptoms of cognitive decline, giving them a little extra time before they develop Alzheimer's. It…
Pam Belluck
Read full article